ACLARION, INC. Proceeds from Notes Payable
ACLARION, INC. (ACON) reported Proceeds from Notes Payable of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-04-09.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2025-04-09
- ACLARION, INC. proceeds from notes payable for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ACLARION, INC. proceeds from notes payable for fiscal 2023 was $2.25M.
- ACLARION, INC. proceeds from notes payable for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- ACLARION, INC. proceeds from notes payable for fiscal 2021 was $2.00M.
| Period end | Proceeds from Notes Payable 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-04-09 |
| 2023-12-31 | $2.25M 10-K · filed 2025-04-09 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-28 |
| 2021-12-31 | $2.00M 10-K/A · filed 2023-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |